
Opinion|Videos|March 21, 2025
Overcoming Key Operational Challenges in Integrating Bispecific Therapies
Experts discuss the most common logistical challenges encountered when implementing bispecific therapies as well as the primary barriers smaller community practices face in operationalizing bispecific antibody treatments.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the most common logistical challenges you encounter when implementing bispecific therapies?
- What are the primary barriers that smaller community practices face in operationalizing bispecific antibody treatments?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
NIH Grant Terminations Disrupt 1 in 30 Clinical Trials, Impacting Over 74,000 Participants
2
How Effective and Safe Are GLP-1s for Weight Loss?
3
Rescue Therapy With Rozanolixizumab Promising in Triple-Seronegative MG
4
FDA Approves Plozasiran to Reduce Triglycerides in Familial Chylomicronemia Syndrome
5
















































